Advertisement

Advertisement

2023 NCCN Annual Congress: Hematologic Malignancies

By Chase Doyle / January 25, 2024 / 2023 NCCN Annual Congress: Hematologic Malignancies

ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy

Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged...

By Chase Doyle / November 25, 2023 / 2023 NCCN Annual Congress: Hematologic Malignancies

Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data

Greater understanding of biological disease factors in acute myeloid leukemia (AML) has led to more effective and personalized treatment options. At the 2023 National Comprehensive Cancer Network (NCC...

Advertisement

Advertisement

Nov

21

Today In Oncology

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

Advertisement

© 2024 HSP News Service, L.L.C.